Dear Readers,

Welcome to the second edition of the Clinical Trials Corner of *Nutrition and Healthy Aging*. The aim of this section is to inform readers of upcoming clinical trials and highlight new findings. If you would like to draw attention to a specific topic and upcoming clinical trials, please email me: <leonie.heilbronn@adelaide.edu.au>

Intermittent fasting (IF) is a nutritional strategy that consists of a period with zero, or minimal food intake, followed by a period where food is freely available. Like moderate daily caloric restriction (CR), intermittent fasting increases life- and health- span in many species including yeast, flies, and mice \[[@ref001]\]. Thus, there is potential for intermittent fasting as a viable alternative to CR to improve health in humans. However, the clinical data as to the safety, efficacy and durability of intermittent fasting is currently limited.

To date, four randomised controlled trials \[[@ref002]\] have compared various forms of intermittent fasting with moderate daily caloric restriction (CR), over 2-12 months. These studies suggest that intermittent fasting is as efficacious to reduce body weight, and may provide greater metabolic benefit vs. CR. There is also accumulating preclinical evidence to show that intermittent fasting protects normal cells against the perils of chemotherapy.

Currently, there are more than 20 clinical trials registered that are examining various modes of intermittent fasting in various cohorts, including teens, overweight, older adults, those with pre-diabetes and undergoing chemotherapy. Highlighted below are 6 of these trials, and we await the outcomes of these studies with great interest.

Yours Sincerely,

<https://www.clinicaltrials.gov/>
=================================

**A). Study Title:** Impacts of intermitted fasting on energy balance and associated health outcomes.

**Clinicaltrials.gov identifier**: NCT02498002

**Sponsor:** University of Bath, UK

**Primary Outcome:** Body Fat Percentage, Lean Body Mass, Fasting Plasma Glucose Concentration, Fasting Plasma Insulin Concentration, Fasting Plasma Triglyceride Concentration, Fasting Total Cholesterol Concentration, Fasting LDL Cholesterol Concentration, Fasting HDL Cholesterol Concentration \[ Time Frame: Baseline - Pre - Post (7 weeks) \]

**B). Study Title:** Intermittent Calorie Restriction, Insulin Resistance and Biomarkers of Brain Function.

**Clinicaltrials.gov identifier**: NCT02460783

**Sponsor:** National Institute on Aging (NIA), USA

**Primary Outcome:** Exosomal p-S312-IRS-1/p-panY-IRS-1 ratio (index of brain insulin resistance) \[ Time Frame: 0, 8 weeks \]

**C). Study Title:** Can Intermitent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?

**Clinicaltrials.gov identifier**: NCT01964118

**Sponsor:** Washington University School of Medicine

**Primary Outcome:** Change in high sensitivity C-reactive protein at 6 and 12 months \[ Time Frame: Every 6 months- baseline, 6 month and 12 month \]

**D). Study Title:** Metabolic and Hormonal Effects of 5:2 Intermittent Fasting

**Clinicaltrials.gov identifier**: NCT02450097

**Sponsor:** Karolinska University Hospital

**Primary Outcome:** Change from baseline in fasting serum insulin in 6 months. \[ Time Frame: 6 months \]

**E). Study Title:** Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers - a Randomized, Controlled, Two-armed Intervention Study With Additional Observational Control Group

**Clinicaltrials.gov identifier**: NCT03162289

**Sponsor:** Charite University, Berlin, Germany

**Primary Outcome:** Functional Assessment of Cancer Therapy - General (FACT-G) \[ Time Frame: Date of inclusion (baseline), day -2 and +7 at each chemotherapy (CT) in triweekly cycles/-2 days at each CT in weekly cycles and +7 after the last weekly CT, 4 months after inclusion, 3 weeks after end of CT and 1, 2 and 3 years after inclusion \]

**F). Dietary restriction as an adjunct to neoadjuvant chemotherapy for HER2 Negative Breast Cancer (DIRECT)**

**Clinicaltrials.gov identifier**: NCT02126449

**Sponsor:** Leiden University Medical Center

**Collaborators:** Borstkanker Onderzoek Groep, Pink Ribbon Inc., Amgen

**Primary Outcome:** The percentage of patients with grade III/IV toxicity according to the National Cancer Institute Common Terminology Criteria for Adverse Events version (NCI CTCAE) v4.03. \[ Time Frame: 2 years \]
